Candiolo Cancer Institute FPO/IRCCS, 10060 Candiolo (TO), and University of Torino, 10100 Turin, Italy.
Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, 1005 Lausanne, Switzerland.
Int J Mol Sci. 2019 Jun 15;20(12):2927. doi: 10.3390/ijms20122927.
Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies. Despite surgery and chemotherapy, 5-years survival rates have improved only modestly over the past few decades remaining at 45% for advanced stages. Therefore, novel therapies are urgently needed. The presence of tumor-infiltrating lymphocytes (TILs) in OC tumor microenvironment (TME) has already proved to be correlated with overall survival (OS), while immune evasion mechanisms are associated with poor prognosis. Although these data indicate that immunotherapy has a strong rationale in OC, single agent immune-checkpoints inhibitors (ICIs) have shown only modest results in this malignancy. In this review, we will discuss immune-targeting combination therapies and adoptive cell therapy (ACT), highlighting the challenges represented by these strategies, which aim at disrupting the stroma-tumor barrier to boost immune system against ovarian cancer.
上皮性卵巢癌（EOC）是妇科恶性肿瘤死亡的主要原因。尽管进行了手术和化疗，但在过去几十年中，晚期患者的 5 年生存率仅略有提高，仍保持在 45%。因此，迫切需要新的治疗方法。肿瘤浸润淋巴细胞（TILs）在 OC 肿瘤微环境（TME）中的存在已经被证明与总生存期（OS）相关，而免疫逃逸机制与预后不良相关。尽管这些数据表明免疫疗法在 OC 中有很强的理论依据，但单一的免疫检查点抑制剂（ICI）在这种恶性肿瘤中的效果仅略好。在这篇综述中，我们将讨论免疫靶向联合治疗和过继细胞疗法（ACT），强调这些策略所面临的挑战，这些策略旨在打破基质-肿瘤屏障，增强免疫系统对卵巢癌的攻击。
Zotero 插件